ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Prevalence and Progression of Subtypes of Gastric Premalignant Lesions: A Systematic Review and Meta-Analysis.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nature reviews. Gastroenterology & hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND &
aimsGastric intestinal metaplasia (IM) and dysplasia are precursor lesions for gastric cancer. This systematic review and meta-analysis examined the global prevalence and progression rates of subtypes of these understudied lesions.
methodsWe searched databases for publications reporting prevalence and progression of subtypes of IM and dysplasia among individuals undergoing endoscopy, including incomplete/complete IM, limited (antrum-restricted)/extensive (corpus-involving) IM, and low-grade dysplasia (LGD) and high-grade dysplasia (HGD). Random-effects models were used to estimate pooled prevalence and progression rates to gastric cancer. The I
resultsEighty-three studies were included for prevalence and 23 for progression. The prevalence of complete IM was 11% (95% confidence interval [CI], 8%-15%) and of incomplete IM was 10% (95% CI, 6%-14%), with corresponding progression rates of 1.73 (95% CI, 1.08-2.79) vs 12.15 (95% CI, 5.28-27.94) per 1000 person-years, respectively (P < .01). The prevalence of limited vs extensive IM was 12% (95% CI, 8%-17%) vs 5% (95% CI, 4%-8%), respectively, and the corresponding progression rates were 3.31 (95% CI, 1.18-9.32) vs 4.19 (95% CI, 0.95-18.41) per 1000 person-years (P = .80). The prevalence of LGD was 2% (95% CI, 1%-4%) and of HGD was 0.28% (95% CI, 0.14%-0.55%), with corresponding progression rates of 11.55 (95% CI, 5.93-22.47) vs 344.48 (95% CI, 144.88-819.09; P < .01). Substantial heterogeneity was observed for all estimates.
conclusionsAlthough lesion subtypes with high progression risk like incomplete IM account for a large portion of the total burden of precancerous lesions, subtyping remains underutilized in clinical practice. Although estimates are limited by heterogeneity, differences in progression rates between lesion subtypes support risk stratification of these lesions within management guidelines, particularly complete vs incomplete IM and LGD vs HGD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.